

# CanVIG-UK Consensus Specification for Cancer Susceptibility Genes (CSGs) of ACGS Best Practice Guidelines for Variant Classification

Date: 13/12/2024 Version: 3.00

A. Garrett<sup>1,2</sup>, S. Allen<sup>1</sup>, L. Loong<sup>1</sup>, M Durkie<sup>3</sup>, J. Drummond<sup>4</sup>, G.J. Burghel<sup>5</sup>, R. Robinson<sup>6</sup>, A. Callaway<sup>7</sup>, J. Field<sup>8</sup>, B. Frugtniet<sup>2</sup>, S. Palmer-Smith<sup>9</sup>, J. Grant<sup>10</sup>, J. Pagan<sup>11</sup>, T. McDevitt<sup>12</sup>, T. McVeigh<sup>13</sup>, H. Hanson<sup>1,14,15</sup>, C. Turnbull<sup>1,13</sup>

- 1) Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
- 2) St George's University Hospitals NHS Foundation Trust, Tooting, London, UK
- 3) Sheffield Diagnostic Genetics Service, NEY Genomic Laboratory Hub, Sheffield Children's NHS Foundation Trust, Sheffield, UK
- 4) East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
- 5) Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, UK
- 6) The Leeds Genetics Laboratory, NEY Genomic Laboratory Hub, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- 7) Central and South Genomics Laboratory Hub, Wessex Genomics Laboratory Service, University Hospital Southampton NHS Foundation Trust, Salisbury, UK.
- 8) Genomics and Molecular Medicine Service, Nottingham University Hospitals NHS Trust, Nottingham, UK
- 9) Institute of Medical Genetics, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, UK
- 10) Laboratory Genetics, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK
- 11) South East Scotland Clinical Genetics, Western General Hospital, Edinburgh, UK.
- 12) Department of Clinical Genetics, CHI at Crumlin, Dublin, Ireland
- 13) The Royal Marsden NHS Foundation Trust, Fulham Road, London
- 14) Peninsula Regional Genetics Service, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK
- 15) Faculty of Health and Life Sciences, University of Exeter, Exeter, UK

## Guidance notes:

- Evidence items for which CanVIG-UK has offered additional specification are shaded in grey. Evidence items are shaded in white where there is no additional specification beyond ACGS Best Practice Guidelines version 1.2 (20/02/2024)<sup>1</sup>.
- **Gene specific guidance for specific CSGs can be viewed at <https://www.cangene-canvaruk.org/gene-specific-recommendations> and should be followed for genes where these exist.** These include CanVIG-UK gene specific guidance and gene specific guidance from ClinGen Sequence Variant Interpretation (SVI) Working Groups (+/- notes from CanVIG-UK).
- Evidence items can be combined using evidence (exponent) points for evidence towards pathogenicity (Very Strong= 8, Strong= 4, Moderate= 2, Supporting= 1) or towards benignity (Very Strong= -8, Strong= -4, Moderate= -2, Supporting= -1). Thresholds:  $\geq 10$  (Pathogenic), 6-9 (Likely Pathogenic), (-1) – (-5) (Likely Benign),  $\leq -6$  (Benign). It is recommended that evidence criteria and evidence (exponent) scores are included on clinical reports.
- $\geq 2$  concordant evidence items are required for a classification of likely pathogenic/pathogenic/likely benign/benign, with the exception of BA1, which provides standalone evidence towards benignity
- Variants should be reported using HGVS nomenclature, including the clinically appropriate transcript and version number (e.g. MANE select and/or MANE clinical plus) and human reference genome build.
- This specification can be used for small sequence variants and intragenic copy number variants. For copy number variants including the whole gene, or overlapping either end of the gene (including UTRs), refer to the ACMG CNV guidance and ACGS Best Practice Guidelines 2024<sup>1,2</sup>. Professional judgement should always be used when evaluating the evidence surrounding a particular genomic variant and assigning a classification.

## Evidence towards Pathogenicity:

### Theme: POPULATION DATA

PS4 (case control): The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls. Relative risk or OR, as obtained from case-control studies, is  $>5.0$ , and the confidence interval around the estimate of relative risk or OR does not include 1.0.

_VSTR	_MOD
_STR	_SUP

<b>Vstrong</b>	$P_{\text{exact}} \leq 0.0025$
<b>Strong</b>	$P_{\text{exact}} \leq 0.05$
<b>Mod</b>	$P_{\text{exact}} \leq 0.1$
<b>Sup</b>	$P_{\text{exact}} \leq 0.2$

	Cases	Controls	Total
Variant	a	b	a+b
WT	c	d	c+d
Total	a+c	b+d	a+b+c+d

#### Explanatory Notes:

- Analysis requires non-duplicated, robustly genotyped case data and control data from **equivalent ethnic groups**. If the ancestry of individuals in case and control datasets is known to differ, PS4 cannot be applied at any strength.
- Nationally/regionally collected datasets or published case data may be used but there should be a minimum of 2 case observations for PS4 to be applied (at any strength).
- For Western European case data, comparison to the UK Biobank White population is recommended as it is currently the largest dataset available with comparable ancestry (i.e. 442,266 White individuals from data retrieved January 2023).
- Estimates of UK Biobank denominator count where there is no count for the variant:
  - It is currently recommended that variant frequency is inferred from inspection at a nearby base at which a variant has been called to ensure denominator count approximates estimated size of subject series
  - If there is no nearby base at which a variant has been called, using a denominator of 95% of the population size is recommended (i.e.  $95\% \times 442,266$  White individuals = 420,152 individuals) to approximate for the frequency at that base, accounting for failed calls.
  - WES data should not be used for intronic data.
- The  $P_{\text{exact}}$  is calculated using the Fishers exact 2-way case control comparison
- The  $P_{\text{exact}}$  does not reflect effect size. Therefore, the Odds Ratio (OR) from the case control comparison ( $ad/bc$ ) should be consistent with the effect size anticipated for that gene type and the lower 95% confidence interval of the OR should be  $>1$ . The OR can be calculated here (tool allows integer or non-integer values).
  - For a 'high penetrance' gene or variant, OR should be  $>5$  for unselected cancer series. For enriched familial cases, a dataset-specific enrichment factor should be used to calculate the OR threshold where available. Otherwise, OR should be  $>10$  for enriched familial cases.
  - For an 'intermediate penetrance' gene or reduced penetrance variant in a high penetrance gene, OR should be  $>2$  for unselected cancer series. For enriched familial cases, a dataset-specific enrichment factor should be used to calculate the OR threshold where available. Otherwise, OR should be  $>4$  for enriched familial cases.
- If the control frequency is 0, the Haldane-Anscombe correction is required to generate an OR (add 0.5 to cells a, b, c, d) (Do not use the Haldane-Anscombe correction for calculation of the  $P_{\text{exact}}$ )
- If there is uncertainty regarding duplicates in the case series, a commensurately more stringent p-value should be applied.

- For non-coding variants, consider use of the WGS partition of UK Biobank (if access available locally). Otherwise, gnomAD v3 may be used.
- Caution should be exercised in using PS4 for CNVs as sequencing approaches/analytical methodologies can result in wide variation in calling of these variant types in NGS/exome/genome data.
  - PS4 can be applied for (i) whole exon or multiexon copy number variants, or (ii) insertions/deletions of 10-50 base pairs. PS4 should not be applied for sub-exonic CNVs of >50bp.
  - PS4 may be applied through case-control analysis as previously described for SNVs, but reduced by one level of evidence strength.

### Case-counting

- Where paired numerator-denominator case frequencies are unavailable, a case-counting approach can be applied.
- For extremely specific rare syndromic cancer susceptibility genes, the UK-ACGS rare disease guidance can be applied. Namely: PS4 can be used at a moderate level of evidence if the variant has not been reported in UK Biobank (in a matched ancestral group) and has been previously identified in multiple (two or more) unrelated affected probands/families with a pathognomonic spectrum of disease, or at a supporting level of evidence if previously identified in one affected individual with a pathognomonic spectrum of disease.
  - In most cases, PM2 should be applicable in order to use PS4 for case-counting.
  - For more common or later onset autosomal dominant disorders, variants with very small numbers of cases in UK Biobank (consistent with disease prevalence and severity/age-of-onset) where PM2 cannot be applied and there are multiple reports in the literature of affected patients but insufficient/no case-control data, PS4 application may still be considered at a maximum of supporting.
- Where the phenotype is less specific, a larger number of observations is required before PS4 should be applied when using a case-counting approach. For example, in the CanVIG-UK BRCA1/2 gene guidance for families with a pattern of diagnoses consistent with a hereditary breast and ovarian cancer syndrome, 5 different families are required for PS4<sub>sup</sub> and 10 for PS4<sub>moderate</sub>.
- Overall, we would recommend that tallying up of specific phenotypic/familial features should generally be incorporated into PP4 rather than PS4, as per CanVIG-UK MMR gene guidance. However, for *TP53*, *PTEN* and *CDH1*, case-counting of specific phenotypic/familial features under PS4 has been issued via the respective ClinGen expert groups<sup>3-5</sup>
- Where case-counting has been performed, PP4/PM3/PP1 cannot be used if 'double-counting' the same specific subphenotype features which rendered the case eligible for use of PS4
- As for case-control analysis, caution should be exercised in using PS4 for CNVs as sequencing approaches/analytical methodologies can result in wide variation in calling of these variant types in NGS/exome/genome data.
  - PS4 can be applied as described for SNV case-counting, however PM2 must also be applied (see using PM2 for CNVs below), noting the caution for CNVs with a similar predicted effect.
    - For CNVs of 3 contiguous exons or larger, use gnomAD v4.1 CNVs **AND** gnomAD v4.1 SVs.
    - For CNVs smaller than 3 contiguous exons, use gnomAD v4.1 SVs only.
  - As for case-control analysis, PS4 should not be applied for sub-exonic CNVs of >50bp.

PM2 (rare in controls): Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or ExAC

\_MOD

\_SUP

Use at **Moderate**: where there are 0 observations of the variant across all populations in gnomAD v4.1

Use at **Supporting** where the variant is not absent but is present at a frequency of  $\leq 0.002\%$  (1 in 50,000 individuals, 1 in 100,000 alleles), or CanVIG-UK/VCEP recommended gene-specific frequency, in the relevant portion of gnomAD v4.1 (see explanatory notes below)

#### Explanatory Notes:

- Note that allele counts from UK Biobank can be retrieved from the CanVar-UK database against the variant searched; for non-SNVs, a spreadsheet of counts is accessible from the CanVar-UK homepage and can be searched manually.
- For PM2\_sup in cancer susceptibility genes, we recommend the use of populations of all ancestries from relevant population databases. Where UK Biobank data has already been used for PS4 application, the non-UK Biobank partition of gnomAD v4.1 should be used to calculate variant frequency to avoid “double-counting”. Where UK Biobank data has not been used for PS4 application, data from the entirety of gnomAD v4.1 should be used to calculate an overall variant frequency.
- PM2 should not be applied at any level if the variant is observed in >1 individual in any subpopulation dataset of <50,000 individuals (e.g. any non-NFE group in gnomAD v4.1)
- ClinGen Sequence Variant Interpretation (SVI) Working Group recommends [applying PM2 criterion at Supporting evidence weighting only](#). CanVIG-UK (in agreement with ACGS working group) recommends retaining of PM2\_Moderate weighting until further ratification of the ACMG guidelines
- Caution should be exercised in using PM2 for CNVs as sequencing approaches/analytical methodologies can result in wide variation in calling of these variant types in NGS/exome/genome data.
  - PM2 may be applied at either moderate or supporting for (i) whole exon or multiexon copy number variants, or (ii) insertions/deletions of 10-50 base pairs.
  - To apply PM2 for CNVs, the variant must be absent (PM2\_mod) or below the defined frequency (PM2\_sup) in population data. Note that for similar-sized CNVs, or those with similar predicted effect (particularly for overlapping in-frame CNVs), over-representation in control datasets of variants with a similar predicted effect could support benignity.
    - For CNVs of 3 contiguous exons or larger, use gnomAD v4.1 CNVs **AND** gnomAD v4.1 SVs.
    - For CNVs smaller than 3 contiguous exons, use gnomAD v4.1 SVs only.
  - PM2 should not be applied at any level for sub-exonic CNVs of >50bp, or where PS4 has already been applied using the same population dataset to measure frequency in controls.
  - Where PS4 has been applied for case-control analysis, PM2 may only be applied if the control data used for PS4 has come from a source other than gnomAD v4.1.
- Where base level allele counts for the control dataset are not available as no variant has been observed at that position, allele counts from nearby bases may be used as an estimate, as per recommendations for PS4 above. Caution should be exercised in using PM2 when the number of alleles sequenced with adequate coverage is unknown both for the specific base and for all nearby bases (more likely relevant for non-exonic variants).
- Caution should be exercised in applying PM2 at any level where the patient has ancestry from populations not well represented in the population databases used.

**Theme: COMPUTATIONAL, PREDICTIVE AND SPLICING IMPACT DATA**

PVS1 (null variant): Null variant (nonsense, frameshift, canonical  $\pm 1$  or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where LOF is a known mechanism of disease

_VSTR	_MOD
_STR	_SUP

For guidance on application of this criteria see Tayoun et al, 2018 (in particular the [PVS1 decision tree](#) and associated notes<sup>6</sup>) and the [ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2024 v1.2](#)<sup>1</sup>

**Explanatory Notes:**

- **Start loss/initiation codon variants:** check if a different functional transcript that uses a different start codon exists. If it does, PVS1 may not be applicable at all
- **Stop gain variants within the first 100bp of the first exon:** for these, nonsense mediated decay (NMD) is likely to be evaded and re-initiation of translation may occur using an alternate start codon<sup>7</sup>
  - Identify whether there is another potential in-frame initiation codon downstream; assess the missing N-terminal region of the protein according to the principles described in the decision tree in Tayoun et al 2018<sup>6</sup> to determine the strength of PVS1 (i.e. is the missing region critical to protein function / is it >10% of the entire protein length / are there  $\geq 1$  pathogenic variant(s) upstream of the potential initiation codon).
  - If no alternative in-frame start codon is identified, use PVS1 at maximum strength according to the gene-disease relationship.
- **Stop loss variants:**
  - When a frameshift occurs near the end of the gene that abolishes the natural termination codon, and a novel termination codon within the 3'UTR is not predicted; the ribosome may stall at the polyA site and not dissociate. Non-stop mediated decay (NSD) will then be triggered, resulting in a null allele (PVS1\_VS)
  - Similarly, NSD and null allele is predicted for base-change variants that abolish the natural termination codon, and where there is no predicted termination codon within the 3'UTR (PVS1\_VS)
  - When a frameshift occurs near the end of the gene and a novel termination codon within the 3'UTR is predicted, neither NMD nor NSD is expected to occur and therefore abnormal and extended protein sequence is predicted. In this case, guidance in Tayoun et al 2018<sup>6</sup> should be followed (use PVS1\_Strong or PVS1\_Moderate depending on functional significance of region and proportion of protein affected)
  - For base change variants that abolish the natural termination codon, and where there is a predicted in-frame termination codon within the 3'UTR: NSD is not predicted and normal protein sequence retained, but extended. In this case, PM4 should be used
- **Variants resulting in a premature termination codon within the last 50bp of the penultimate exon or within the final exon:** these are generally not predicted to undergo nonsense mediated decay.
- **Canonical splice variants at the exon 1/intron 1 donor site and final intron donor/acceptor sites:** should be treated with care. Quantitative RNA studies should be sought to confirm abnormal splice effect.

- **Splicing variants at +2T>C:** may result in functional GC splice sites and PVS1 should be used cautiously in the absence of RNA studies<sup>8</sup>. Use of SpliceAI is recommended to assess the likely impact on splicing. If Splice AI delta score  $\geq 0.8$  PVS1 can be applied.
- **Exon level events such as deletions that are in-frame or not predicted to undergo NMD or duplications not demonstrated in tandem, or  $\pm 1, 2$  splicing variants where the reading frame is preserved,** are at most a moderate or strong level of evidence, and without published studies may not be eligible for PVS1 at all. Without robust case-control data, these may be difficult to establish as likely pathogenic/pathogenic. For variants that require evidence of “region critical to protein function”, looking at clinically significant variants in the region can be a good indicator of a functionally significant region. Generally, missense variants demonstrated as pathogenic (and high penetrance) by independent lines of evidence, can be used to upgrade from moderate to strong (assuming they are not acting on splicing). However, care should be taken to determine if variants ascribed as clinically significant have been classified using up to date guidelines. For example, when looking at frameshift or protein truncating variants in databases such as ClinVar, factors such as the date of submission and evidence used should be considered
- **In-frame insertion/deletion events of less than exon size:** refer to PM4 instead of PVS1
- **For single and multi-exon insertions/deletions up to whole gene deletions:** use PVS1 decision tree from Tayoun et al, 2018<sup>6</sup>
- **For large insertion/deletion events involving multiple genes (e.g. detected on microarray or whole genome sequencing):** refer to ACMG copy number variant guidance<sup>2</sup> and SASI guidance for specific cancer susceptibility genes<sup>9</sup>

PVS1\_RNA: Observed splicing defect in functional study

_VSTR	_MOD
_STR	_SUP

Where variants are shown to impact splicing by RNA- or cDNA-based assays, the PVS1\_RNA code may be applied, even where PVS1 may not ordinarily be applied on the basis of variant type or location. The applicable strength of PVS1\_RNA is determined by evaluating the impact of the observed RNA change(s) as per PVS1 recommendations (either gene-specific or general, as specified by Tayoun et al, 2018<sup>6</sup>, Walker et al, 2023<sup>10</sup>).

**Additional guidance:**

- See combinations table for combining PVS1\_RNA with other evidence codes (PS3, PS1, PP3, PM4, PVS1)
- PVS1\_RNA and BP7\_RNA may only be applied at full strength if the assay was conducted using non-tumour tissue samples<sup>10</sup>
- Consider downgrading PVS1\_RNA strength where there is evidence of some leakiness (see “Leakiness”, below). Do not apply PVS1\_RNA if there is evidence of extreme leakiness or where there is a plausible rescue model based on the observation of naturally occurring alternative splice transcripts.<sup>10</sup>
- The exon in question must be present in the biologically relevant transcript(s)
- Consideration should be given to the relationship between the biological activity of the clinically accessible tissue (e.g. blood/fibroblasts) and the disease tissue; tools such as the Human Protein Atlas (<https://www.proteinatlas.org/>) provides information on transcript expression levels and tissue distribution.

- If predictive data from splicing *in silico* tools is discordant with splicing assay data, the evidence from *in silico* tools may be disregarded in favour of assay results.

### Assay Validation Requirements

Assays must be performed in a diagnostically ISO accredited laboratory or recognized research laboratory with which direct consultation can be undertaken. **If all evidence is derived from an alternative source (e.g. publication only), downgrade by one level of evidence.**

- All assays should evidence appropriate validations and controls. Controls should ideally be tissue-matched.
- Laboratory methodology should be appropriately validated: e.g. primers have been tested in  $\geq 5$  independent normal control reactions, not necessarily run at the same time (i.e. primers could be validated using 5 normal controls across several runs or runs as a batch on a single run). Further considerations for splicing assay design and interpretation of splicing results are included in table S9 of Walker et al., (2023).
- Experimental data may include:
  - Quantitative assays (e.g. realtime-PCR, Sanger sequencing with formal quantitation of peak height, tape-station quantification of PCR products, minigene assay, RNAseq using NGS, massively parallel reporter assays). Since a minigene assay is construct-based, when used alone consideration should be given to reduce the evidence weighting to accommodate the limitations associated with being an artificial system<sup>10</sup>.
  - Semi/non-quantitative assays (e.g. visual evaluation of the relative peak height using Sanger sequencing, gel-based evaluation and visualisation of reverse transcriptase PCR (RT-PCR) products, or analysis for evidence of nonsense mediated decay, such as where a SNV *in trans* with the putative splicing variant appears homozygous on RNA sequencing despite being heterozygous on DNA sequencing, indicating the loss of expression of the transcript containing the putative splicing variant).

**'Leakiness'**: Although there will inevitably be gene-by-gene and exon-by-exon variation regarding the lower limit of % normal transcripts ('leakiness') at which normal protein function is maintained, this information is not always known. In the absence of specific data for a given gene/exon, the following thresholds of 'leakiness' should be applied:

- **No evidence of leakiness:** >40% aberrant isoform expression/splice junction usage observed in assay
  - == underlying >80% splicing aberration per allele, assuming heterozygosity
  - Do not downgrade PVS1\_RNA
- **Evidence of some leakiness:** >10% aberrant isoform expression/splice junction usage observed in assay
  - == underlying >20% splicing aberration per allele, assuming heterozygosity
  - Downgrade the level of PVS1\_RNA by 1 strength
- **Evidence of extreme leakiness<sup>9</sup>:** <10% aberrant isoform expression/splice junction usage observed in assay
  - == underlying <20% splicing aberration per allele, assuming heterozygosity
  - Typically, abnormal transcript will be visible on gel but present only at extremely low level, or not visible by Sanger sequencing
  - **Do not apply PVS1\_RNA**

The accuracy of different assays and/or bioinformatics approaches in correctly quantifying ratios of different transcripts will vary and is often poorly quantified. As improved data on the precision of different assays/tools emerges, these standards will likely be amended.

Naturally occurring (i.e. non-pathogenic) splice variants have been catalogued by expert groups for some genes. Please see [gene specific recommendations](#).

See **Walker et al., 2023<sup>10</sup>** and the **ClinGen SVI Splicing Subgroup Response to Feedback document<sup>11</sup>** for further advice on application.

PS1 (same amino acid change): Same amino acid change as a previously established pathogenic variant, regardless of nucleotide change

_MOD
_STR
_SUP

**For consideration of protein impact:**

- Use at **Strong** for a missense or initiation codon variant under evaluation where there is a reference missense or initiation codon variant classified as pathogenic **AND** the variant under assessment has a similar (a difference in scores of  $\leq 0.02$ ) or more deleterious REVEL prediction than the reference variant, or both variants have REVEL scores of  $\geq 0.773$ <sup>12</sup>
- Use at **Moderate** for a missense or initiation codon variant under evaluation where there is a reference missense or initiation codon variant classified as likely pathogenic **AND** the variant under assessment has a similar (a difference in scores of  $\leq 0.02$ ) or more deleterious REVEL prediction than the reference variant, or both variants have REVEL scores of  $\geq 0.773$ <sup>12</sup>

**For consideration of splicing impact:**

The below table is adapted from Walker et al., 2023<sup>10</sup>. Refer to this paper and the additional notes below for further advice on applying PS1.

Variant under assessment (VUA)	Baseline computational/predictive code applicable to VUA	Position of comparison variant relative to VUA	PS1 code applicable to VUA	
			with P comparison variant	with LP comparison variant
Located outside splice donor/acceptor $\pm 1,2$ dinucleotide positions	PP3	same nucleotide	PS1	PS1_Moderate
	PP3	within same splice donor/acceptor motif (including at $\pm 1,2$ positions)	PS1_Moderate	PS1_Supporting
Located at splice donor/acceptor $\pm 1,2$ dinucleotide positions	PVS1	within same splice donor/acceptor $\pm 1,2$ dinucleotide	PS1_Supporting	N/A
	PVS1	within same splice donor/acceptor region, but outside $\pm 1,2$ dinucleotide <sup>a</sup>	PS1_Supporting	PS1_Supporting
	PVS1_Strong, PVS1_Moderate, or PVS1_Supporting <sup>b</sup>	within same splice donor/acceptor $\pm 1,2$ dinucleotide	PS1	N/A <sup>c</sup>
	PVS1_Strong, PVS1_Moderate, or PVS1_Supporting <sup>b</sup>	within same splice donor/acceptor motif, but outside $\pm 1,2$ dinucleotide <sup>a</sup>	PS1_Moderate	PS1_Supporting

Prerequisite for all: the predicted event of the variant under assessment (VUA) must precisely match the predicted event of the comparison (likely) pathogenic variant (e.g., both predicted to lead to exon skipping, or both to lead to enhanced use of a cryptic splice motif, AND the strength of the prediction for the VUA must be of similar or higher strength than the strength of the prediction for the comparison [likely] pathogenic variant). For an exonic variant, predicted or proven functional effect of missense substitution(s) encoded by the VUA and (likely) pathogenic variant should also be considered before application of this code. Dinucleotide positions refer to donor and acceptor dinucleotides in reference transcript(s) used for curation. Designated donor and acceptor motif ranges should be based on position weight matrices for intron category (see methods). For GT-AG introns these are defined as follows: the donor motif, last 3 bases of the exon and 6 nucleotides of intronic sequence adjacent to the exon; acceptor motif, first base of the exon and 20 nucleotides upstream from the exon boundary. Consider other motif ranges for non-GT-AG introns.

<sup>a</sup>If relevant, splicing assay data for a pathogenic variant outside a  $\pm 1,2$  dinucleotide position may be used to update a PVS1 decision tree and hence the applicable PVS1 code for a  $\pm 1,2$  dinucleotide variant.

<sup>b</sup>Where PVS1\_strong, PVS1\_mod or PVS1\_sup has already been applied for the VUA, consider application of PS1 at a reduced level if clinical data has been used to classify reference variant



After discussion with SVI leadership, PS1\_mod/PS1\_sup may be applied at user discretion depending on the availability and quality of clinical data used to support reference variant classification. E.g. PVS1\_strong and PS1\_moderate should NOT be used together to classify a variant as likely pathogenic in the absence of supporting clinical data

**Additional notes (relevant for both protein and splicing impact):**

- See combinations table for combining PS1 with other evidence codes (PVS1\_RNA, PP3, PVS1)
- PP3 must be applicable for PS1 to be applied
- Reference variants must have been classified using ACMG guidance and/or have a 3\* classification on ClinVar.
- For splicing impact prediction, both the reference variant and variant under examination should have SpliceAI scores of  $\geq 0.2$  and have the same predicted splicing impact.
- PS1 cannot be used where the variant under evaluation:
  - has functional data with equivalent mechanism of action (i.e. both variant under evaluation and reference variant acting through splicing impact or both acting through protein impact) from a BS3\_strong/medium-graded assay indicating benignity OR
  - multiple functional assays are contradictory

PM4 (length change): Protein length changes as a result of in-frame deletions/ insertions in a non-repeat region or stop-loss variants

\_MOD  
\_SUP

PM4 should be applied with caution in poorly conserved regions. In silico tools such as MutPred-Indel and Ensembl VEP can be used to support the decision to apply PM4.

Use at **Moderate** for

- In-frame insertions/deletions of >1 amino acid
- Stop-loss variants where there is an in-frame termination codon in the 3'UTR and NMD is not predicted

Use at **Supporting** for

- In-frame insertions/deletions of a single amino acid

PM5 (same codon): Missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before

\_MOD  
\_SUP

Use at **Moderate** if

- Variant under examination has similar or higher REVEL score than reference variant ("similar" is taken as a difference in scores of  $\leq 0.02$ ) or both reference variant and variant under examination have REVEL scores of  $\geq 0.773^{12}$ .

Use at **Supporting** if

- Reference variant is classified as LP AND has only been reported in 1 individual AND/OR
- Variant under examination has a REVEL score of  $>0.7$  and  $<0.773^{12}$  AND is LESS deleterious than the REVEL score of the reference variant

**Explanatory notes:**

- Reference variant must have been classified using ACMG guidance and/or have a 3\* classification on ClinVar. It should not be predicted to affect function through alterations to splicing
- PM5 can only be used in conjunction with PS3 (functional data) if the reference variant can be classified as (likely) pathogenic without using functional data
- PM5 cannot be used where the variant under evaluation:
  - has functional data from a BS3\_strong/medium-graded assay indicating benignity OR
  - multiple functional assays are contradictory

PP3 (in silico): Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact)			_SUP
<ul style="list-style-type: none"> <li>Protein impact: <ul style="list-style-type: none"> <li>Use of a meta-predictor tool such as Revel (&gt;0.7)<sup>13</sup> Use of multiple tools is no longer recommended.</li> </ul> </li> <li>Splicing impact: <ul style="list-style-type: none"> <li>Intron-exon boundary: <a href="#">SpliceAI</a> (any <math>\Delta</math> score <math>\geq 0.2</math>)<sup>14</sup> OR</li> <li>MaxEnt &gt;15% difference <b>AND</b> SSFL &gt;5% difference<sup>15</sup></li> </ul> </li> </ul>			
PM1/PP2 (constraint/enrichment):			_MOD
PP2: Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease.	_STR		_SUP
PM1: Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation			
<ul style="list-style-type: none"> <li>PP2 is applied when encountering a rare missense variant in an individual with the appropriate phenotype where there is enrichment for pathogenic missense variation and constraint for benign missense variation in that <b>gene</b> (<math>Z \geq 3.09</math>)</li> <li>PM1 can be used <b>instead</b> when the variant lies in a region/domain for which there is greater enrichment for pathogenic missense variation and constraint for benign missense variation</li> <li>PP2 and PM1 <b>cannot</b> be used in combination</li> <li>Tools such as Decipher (<a href="https://www.deciphergenomics.org/">https://www.deciphergenomics.org/</a>) and Alamut may assist with the identification of functional domains and hot spots containing a high ratio of ClinVar classified pathogenic/likely pathogenic to gnomAD observed variants</li> </ul> <p><b>Explanatory Notes:</b></p> <ul style="list-style-type: none"> <li>Use PP2 at <b>Supporting</b> where there is overall constraint for missense variation at the level of the region/exon/gene (<math>Z \geq 3.09</math>). Where data exists defining regional enrichment, this should be used in place of gene level data (i.e. PM1 in place of PP2)</li> <li>Enrichment for pathogenic missense variation and constraint for benign missense variation is best quantified using appropriate likelihood ratios (LRs). Where such data is available, the corresponding evidence level in accordance to the LR should be used. In the absence of LR: <ul style="list-style-type: none"> <li>Use PM1 at <b>Moderate</b> for a variant in a mutational hotspot at which there is no benign variation</li> <li>Use PM1 at <b>Supporting</b> for a variant in a mutational hotspot at which there is limited benign variation.</li> </ul> </li> </ul>			

<b>Theme: FUNCTIONAL DATA</b>			
PS3 (functional data): Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product		_VSTR	_MOD
		_STR	_SUP
<p>This criterion is for ex-vivo variant-specific analyses. Where an assay in the individual patient provides support (e.g. biochemical analysis), this should typically be incorporated within the phenotypic specificity criterion PP4. For functional assays reporting of splicing impact, please see PVS1_RNA or BP7_RNA.</p> <p><b>Explanatory Notes</b></p> <ul style="list-style-type: none"> <li>Variant is considered to have functionally abnormal effect if protein activity assay or functional impact is &lt;25% of wildtype level</li> </ul>			

- Assay weighting for PS3 should be determined in accordance with Clinical Genome Resource SVI recommendations<sup>16</sup>. Variants used as positive/negative controls should have been classified by an ACMG/expert group as (likely) benign/(likely) pathogenic. See summary of [functional studies reviewed by CanVIG-UK](#) in accordance to Brnich et al (2020) principles<sup>16</sup>. an adjusted OddsPath methodology (+0.5 not +1) is recommended in accounting for the incidence of True Positive(s)/Negative(s) and False Positive(s)/Negative(s) in variant validation.
- Where data from multiple assays is available:
  - In the instance of conflicts between functional assays of similar evidence strength (STRONG/STRONG, STRONG/MOD, MOD/MOD or Mod/SUP or SUP/SUP) according to evaluation methods described by Brnich et al (2020)<sup>16</sup>, refer to the tables below
  - Where concordant, or (as per tables below) there is a permitted discordancy, the evidence level afforded for the combination of the two assays is that of the higher scoring assay
  - Where assays are discordant and of significantly different evidence strengths, the lower-ranked assay should be discarded
  - If differences between functional assay results can be explained by differences in the functional mechanisms incorporated into the assays (for example LOF mediated through an effect on splicing is seen on one assay but the variant appears functional on an assay which would not detect splicing effects), this should not be treated as a conflicting result

*Two 'single-element' assays*

		Assay 2				
Assay 1		LOF	INT (towards LOF)#	INT (towards FUNC)#	INT (no quantitation provided)	FUNC
	LOF	PS3	PS3	x	x	x
	INT- (towards LOF)#	PS3	x	x	x	x
	INT (towards FUNC) #	x	x	x	x	BS3
	INT (no quantitation provided)	x	x	x	x	x
	FUNC	x	x	BS3	x	BS3

*Two assays where Assay 1 comprises multiple sub-elements*

		Assay 2			
Assay 1		LOF	INT- (towards LOF)#	INT (towards FUNC)#	FUNC
	All deleterious/ likely deleterious/Intermediate (towards LOF)#*	PS3	PS3	x	x
	Mixed deleterious/neutral/intermediate	x	x	x	x
All neutral/likely neutral/Intermediate (towards functional)#**	x	x	BS3	BS3	

#The numeric mid-point of the intermediate range for the functional assay should be used as the cut off for towards LOF vs towards functional  
 \*If no quantitation of intermediate scores is provided, only one intermediate score is allowed. There must be two or more deleterious/likely deleterious results  
 \*\*If no quantitation of intermediate scores is provided, only one intermediate score is allowed. There must be two or more neutral/likely neutral results

**Theme: SEGREGATION DATA**

PP1 (co-segregation with disease): Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease

_VSTR	_MOD
_STR	_SUP

See [Jarvik and Browning \(2016\)](#)<sup>17</sup>

**Theme: DE NOVO DATA**

PS2, PM6 (de novo): PS2: De novo (both maternity and paternity confirmed) in a patient with the disease and no family history. PM6: Assumed de novo, but without confirmation of paternity and maternity

_VSTR	_MOD
_STR	_SUP

See [ClinGen SVI Recommendation for de novo Criteria](#)

**Theme: ALLELIC DATA**

PM3 (in trans): For recessive disorders, detected in trans with a pathogenic variant

	_MOD
_STR	_SUP

Use [SVI recommendations for in trans Criterion \(PM3\)](#)

**Explanatory Notes:**

- Comprehensive analysis should be undertaken for the gene to exclude an alternative second pathogenic mutation (e.g. including MLPA) in that gene
- Comprehensive analysis should be undertaken for all other genes for which the phenotypic features overlap
- Requires testing of parents (or offspring) to confirm phase
- Can use for homozygous variants but downgrade by one evidence level
- Caution is required in inferring the pathogenicity for the monoallelic phenotype, as variants may be hypomorphic (e.g. a variant contributing and causing ataxia-telangiectasia may be low penetrance for breast cancer)

**Theme: OTHER DATABASES/DATA**

*PP5 (reputable source): Reputable source recently reports variant as pathogenic*

*This code is no longer valid. Where required for classification, the specific contributory evidence should be sought directly from the group who has undertaken the variant classification under examination.*

PP4 (phenotypic specificity): Patient's phenotype or family history is highly specific for a disease with a single genetic aetiology

	_MOD
_STR	_SUP

- PP4 is applied to reflect presence of **clinical or cellular/molecular** 'subphenotypic elements' that strongly implicate the relevant gene (or small gene-set)
- Comprehensive analysis (including CNV analysis) of the gene and related genes should have been undertaken to exclude an alternative pathogenic variant

- Evidence can be summed across multiple families:
  - Total points: Supporting: 1; Moderate: 2; Strong: 4
  - Only one individual per family can contribute
- Where supplied, the inverse evidence must be applied (e.g. if loss of staining for IHC is evidence towards pathogenicity, then retention of staining is evidence against pathogenicity)

LR	Evidence Points	Level	Cellular/molecular phenotype	Example
>1.4:1	0.5	-	Moderately predictive for germline aberration of one of a small set of genes	Eg: For <i>MLH1</i> variant with <i>MLH1</i> promoter methylation status unknown <ul style="list-style-type: none"> <li>• MSI high <b>AND/OR</b></li> <li>• Loss on immunohistochemistry (IHC) of <i>MLH1</i>+/-<i>PMS2</i> <b>AND/OR</b></li> </ul> Loss of <i>MLH1</i> on IHC ( <i>PMS2</i> IHC status unknown)
>2.1:1	1	<b>Sup</b>	Highly predictive for germline aberration of one of a small set of genes <b>OR</b> Moderately predictive for germline aberration of the specific gene (rare phenotype) <b>OR</b> Highly predictive for germline aberration of the specific gene (common phenotype)	Informative LOH at chromosomal locus of tumour-suppressor gene  For <i>MSH2</i> or <i>MSH6</i> variant in colorectal cancer <ul style="list-style-type: none"> <li>• MSI high <b>AND/OR</b></li> <li>• Loss on IHC of protein pair/appropriate single protein</li> </ul>
>4.3:1	2	<b>Mod</b>	Highly predictive for germline aberration of the specific gene (rare phenotype)	For <i>SDHB</i> or <i>SDHD</i> variant in pheochromocytoma/paraganglioma <ul style="list-style-type: none"> <li>• Loss of <i>SDHB</i> on IHC <b>AND/OR</b></li> <li>• SDH Succinate:Fumarate Ratio high<sup>18</sup></li> </ul>

#### Explanatory Notes:

##### For 'clinical' subphenotypic elements

- Use of PP4 is only advised where there has been explicit specification for evidence strength for the relevant 'subphenotypic' element (either via explicit numeric quantitation and/or via explicit guidance)
  - For common, non-specific CSG subphenotypic elements (e.g. aspects of breast and/or ovarian cancer), PP4 should only be used where there has been explicit quantitation for phenotypic specificity (e.g. 'Family History LLR for *BRCA1/2*, see relevant [gene-specific guidance](#))
  - For rarer CSG subphenotypic elements (e.g. phaeo/PGL), PP4 can be used as per the calculated likelihood ratio for subphenotypic elements (e.g. multiple vs. solitary, familial vs. sporadic, invasive vs. non-invasive)

- For more specific pleomorphic syndromic CSG presentations for which the clinical subphenotypic elements have been included in the ClinGen Expert Group case-definition for PS4 case-counting (e.g. *CDH1*, *PTEN*, *TP53*<sup>3-5</sup>), PP4 cannot be used for clinical subphenotypic elements

#### For ‘cellular/molecular’ subphenotypic elements

- Individuals/tumours included must have been demonstrated to carry the germline mutation
- Up to two **independent** tumour phenotype assays can be included per case (e.g. MSI AND LOH). Strongly correlated (non-orthogonal) tumour phenotypes from the same case cannot both be included, e.g. MSI and IHC

### Evidence towards Benignity:

#### Theme: POPULATION DATA

BA1/BS1 (common in controls): Allele frequency is “too high” for disorder (Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium)

\_SA

\_STR

For use in dominant conditions for alleles of standard penetrance:

Use **BA1** as **Stand\_Alone** when the allele frequency in any ethnicity-specific subpopulation of >1000 individuals, or mixed population of >5000 individuals is:

- >1% for well characterised cancer susceptibility genes<sup>19</sup> OR
- The Grpmax Filtering allele frequency (Grpmax FAF) given in gnomAD v4.1 is greater than the BA1 maximum tolerated allele frequency (MTAF) threshold specified for the specific gene by respective expert group (VCEP/CanVIG guidance documents). See explanatory notes below.

Use **BS1** as **Strong** when the Grpmax FAF given in gnomAD v4.1 is greater than the BS1 MTAF threshold (but less than the BA1 MTAF threshold) specified for the specific gene by respective expert group (VCEP/CanVIG guidance documents).

Note that various gene-specific guidance (including *BRCA1/2* and *PALB2*) require only females to be included in the reference population dataset, in this instance the maximum tolerated allele count (AC) should be calculated using the *Calculate AC* tool in [cardiodb](#). Alternatively, the filtering allele frequency (FAF) can be calculated using the *InverseAF* tool in [cardiodb](#) which gives a value which can be compared to the MTAF thresholds for BA1/BS1 (see explanatory notes below).

Reference population data from UK Biobank may be used, and the maximum tolerated AC or FAF should be calculated using [cardiodb](#) (see explanatory notes below).

#### Explanatory Notes:

Maximum tolerated allele frequency (MTAF) and filtering allele frequency (FAF) thresholds are used interchangeably in various expert group guidance documents.

Grpmax FAF:

The Grpmax FAF is the lower 95% confidence interval estimate of the allele frequency from the continental subpopulation with the highest FAF (excluding ASJ, FIN, OTH)

The Grpmax FAF is displayed in gnomAD v4.1. The value given is dependent on the dataset chosen, so ensure that the most appropriate population is chosen (e.g. gnomAD v4.1).

There are calculated Grpmax FAF values for both the genomes and exomes dataset in gnomAD; generally the exomes dataset will contain more alleles and this one should be used.

Calculating the maximum tolerated allele count (AC) and filtering allele frequency (FAF):

**To determine the maximum tolerated AC**, use the *Calculate AC* tool in [cardiodb](#) (see [training resources](#) from Miranda Durkie for methodology); note in [cardiodb](#), the *Maximum population AF* (MTAF threshold) should be input as a decimal between 0-1 (rather than a percentage). The maximum tolerated AC should be compared to the actual variant allele count in the reference population; if the actual allele count is greater BA1/BS1 can be applied (as appropriate to the input MTAf).

**To determine the FAF of a population**, use the *InverseAF* tool in [cardiodb](#); the FAF can be compared to the MTAf thresholds for BA1/BS1. If the FAF is greater than the threshold MTAf for BA1 use BA1; if the FAF is greater than the threshold MTAf for BS1 (but less than the BA1 threshold) use BS1.

Caution should be applied if using bottlenecked or poorly defined populations in gnomAD (i.e. ASJ, FIN, OTH) as reference populations in the calculation of the FAF / maximum tolerated AC; it is acceptable to use (one or more of) the remaining continental subpopulations as a reference population.

Reference populations should be >5000 alleles (mixed) or >1000 alleles (ethnicity-specific).

### Theme: COMPUTATIONAL, PREDICTIVE AND SPLICING IMPACT DATA

BP4 (bioinformatic tools): Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.)

\_SUP

- Protein impact:
  - Use of a metapredictor tool such as Revel (<0.4)<sup>13</sup>. Use of multiple tools is no longer recommended.
- Splicing impact:
  - Intron-exon boundary: [SpliceAI](#) (all  $\Delta$  scores <0.1) OR
  - MaxEnt <5% difference AND SSFL <2% difference AND no evidence of prediction of exonic/deep intronic novel splice site of any strength

BP1: Missense variant in a gene for which primarily truncating variants are known to cause disease

\_SUP

Use at **Supporting** for genes/gene regions in which >95% of reported pathogenic variants are truncating e.g. APC, PALB2

#### Explanatory Note:

Splicing prediction tools e.g. [SpliceAI](#) should be applied to exclude potential impact on splicing (see evidence line BP4)

BP3 (in-frame deletion): In-frame deletions in a repetitive region without a known function

\_SUP

<b>Explanatory Note:</b>	
Particularly relevant to poorly conserved regions. In silico tools such as MutPred-Indel and Ensembl VEP can be used to help support application of BP3.	
BP7 (synonymous): A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved	_SUP
<b>Explanatory Note:</b>	
BP7 can be applied for the follow variant types, provided (i) they are in regions that are not highly conserved (defined as those with PhastCons score <1 and/or PhyloP score <0.1) and that (ii) BP4 is also met (ie no splicing effect predicted)	
<ul style="list-style-type: none"> <li>• synonymous variants</li> <li>• intronic variants at or beyond +7/-21</li> <li>• non-coding variants in UTRs</li> </ul>	
BP7_RNA: No observed splicing defect in splice impact study	_STR
See Walker et al., 2023 <sup>10</sup> for further details on application from the ClinGen SVI Splicing group:	
<ul style="list-style-type: none"> <li>• Apply at <b>Strong</b> for Silent/Intronic variants outside the designated splice region with data from a splicing assay showing no predicted functional effect</li> <li>• Apply at <b>Strong</b> for other variant types (e.g. missense/in-frame) where data from a splicing assay showing no predicted effect <b>AND</b> protein impact has been shown to be normal based on functional and/or clinical data.</li> <li>• For variants affecting the coding sequence e.g. missense/in-frame variants: if there is no available protein functional data, BP7_RNA should not be applied.</li> <li>• BP7_RNA may be applied in combination with predictive codes (PP3/BP4)</li> <li>• BP7_RNA may only be applied if the assay was conducted using non-tumour tissue samples<sup>10</sup>. See PVS1_RNA for further guidance regarding assay validation requirements.</li> </ul>	

<b>Theme: FUNCTIONAL DATA</b>	
BS3 (functional data): Well-established in vitro or in vivo functional studies show no damaging effect on protein function	_MOD _SUP
Weighting of BS3 should be determined according to assay criteria defined by Clinical Genome Resource SVI recommendations (Brnich et al, 2020) <sup>16</sup> . Variants used as positive/negative controls should have been classified by an ACMG/expert group as (likely) benign/(likely) pathogenic. See summary of <a href="#">functional studies reviewed by CanVIG-UK</a> in accordance to Brnich et al (2020) principles <sup>16</sup> . An adjusted OddsPath methodology (+0.5 not +1) is recommended in accounting for the incidence of True Positive(s)/Negative(s) and False Positive(s)/Negative(s) in variant validation. For functional assays of splicing impact, please see PVS1_RNA or BP7_RNA.	
<b>Additional Note:</b>	
BS3 should not be applied for an assay of protein function when <i>in silico</i> tools predict effect on splicing and/or for the first or last three bases of the exon.	

<b>Theme: SEGREGATION DATA</b>	
BS4 (non-segregation): Non segregation with disease	_STR _SUP



See [Jarvik and Browning \(2016\)](#)<sup>17</sup>

Caution should be exercised in applying BS4 in cancer susceptibility genes associated with common or non-specific phenotypes and where cancers are associated with pathogenic variants in several different cancer susceptibility genes

### Theme: ALLELIC DATA

BS2/BP2 (observation in trans/cis).

**\_STR** **\_SUP**

BS2: Observation in controls inconsistent with disease penetrance. Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.

BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern

Use BP2 or BS2 at **Supporting** where no further genotyping or clinical/cellular phenotyping is possible

Use BS2 at **Strong** where:

- laboratory analysis has been repeated using an orthogonal approach (e.g. different primers) to confirm homozygosity for allele AND
- patient is of age at which biallelic variants would be anticipated to be penetrant for a distinctive phenotype AND
- patient has been actively examined to exclude relevant phenotype AND/OR had analysis of cellular phenotype

OR the homozygote is observed in a specified control population in addition to a heterozygote frequency meeting BS1

Use BP2 at **Strong** where:

- alleles have been confirmed as in trans AND
- patient is of age at which biallelic mutations would be anticipated to be penetrant for a distinctive phenotype AND
- patient has been actively examined to exclude relevant phenotype AND/OR had analysis of cellular phenotype

#### Explanatory Notes:

- BS2 should only be used in the recessive context and for observation of a **homozygote**
- BP2 is used for where the variant is reported as a **compound heterozygote** in conjunction with a pathogenic variant in unaffected individual

For cancer susceptibility genes, **BP2 and BS2** should only be used for those genes in which typical (non-hypomorphic) biallelic variants cause a recognised phenotype that is fully penetrant from infancy. Such genes include *BRCA1*, *BRCA2*, *PALB2*, *MLH1*, *MSH2*, *MSH6* and *PMS2*

### Theme: OTHER DATABASES/DATA

*BP6 (reputable source): Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation*

*This code is no longer valid. Where required for classification, the specific contributory evidence should be sought directly from the group who has undertaken the variant classification under examination.*

BP5 (alternative molecular basis): Variant found in a case with an alternate molecular basis for disease


**\_SUP**

The application of this evidence line is limited in cancer susceptibility genes: only applicable to rare, highly penetrant, dominant syndromic phenotype(s), in which family history is available (e.g. finding of a variant in VHL in a patient with pheochromocytoma in whom a pathogenic *SDHD* variant is subsequently identified)

**Explanatory Note:**


**This should not be applied** for autosomal dominant incompletely penetrant non-syndromic genes associated with common cancers e.g. HBOC (hereditary breast and ovarian cancer). Co-occurrence of  $\geq 2$  pathogenic variants in different cancer susceptibility genes is widely reported. Typically, the phenotype exhibited is indistinguishable from that of a single pathogenic mutation.

## Combinations: towards pathogenicity



1	PM4	PVS1	<b>Not permitted;</b> PM4 is used for in-frame deletions/insertions that are small ( $\leq 1$ exon length), PVS1 is used for larger in-frame multi-exon deletions/duplications
2	PS4	PP4	<b>Caution:</b> Can not be combined if case-counting used for PS4 and phenotypic features have been included in case-definition
3	PM2	PS4	<b>Caution:</b> The same control series can not be used for PM2 and PS4. Can be combined where a second control series is available
4	PVS1	PM1	<b>Not permitted;</b> PM1 is reserved for missense/small insertions-deletions
5	PM4	PM1	<b>Permitted:</b> PM1 can be used for missense or small (localised) insertions or deletions
6	PP2	PM1	<b>Not permitted;</b> PP2 is used for constraint at gene level, PM1 is used for constraint at domain level. *this has been updated from recommendations in Garrett et al 2020 with emergence of more evolved analyses of case-control constraint
7	PVS1	PM5	<b>Caution;</b> PM5 application is reserved for missense variants, except where use of PM5 and PVS1 in combination is recommended by gene-specific guidance
	PM4	PM5	
	PP2	PM5	
	PM1	PM5	
8	PP2	PS1	<b>Not permitted;</b> Where points are awarded for substitution at the same residue/ of the same amino acid, additional points can not be awarded for constraint at gene/domain level. A variant for which functional data is used for PS3 or BS3 can not be awarded PM1, as typically functional data informs delineation of a domain/hot-spot.
	PM1	PS1	
	PM1	PS1	
	PM1	PS3	
9	PS1	PP3	<b>Caution:</b> For application of PS1 in the context of splicing, predictive tools (PP3 or PVS1) should demonstrate a predicted impact on splicing as per the Walker et al., 2023 guidance <sup>10</sup> . Codes may be applied in combination (PS1 + PP3 or PS1 + PVS1), please see the table in the PS1 section of this document for examples.
	PS1	PVS1	
10	PS1	PM5	<b>Not permitted;</b> PS1 supersedes PM5
11	PVS1	PP3	<b>Not permitted;</b> PVS1/PM4 are awarded for prediction of a pro-pathogenicity mechanism; PP3 can not be used additionally
	PM4	PP3	
12	PM5	PP3	<b>Caution:</b> PP3 can not be used where PM5 is used at moderate/strong on account of variant having higher Revel score than reference variants
13	PM4	PS3	<b>Restriction:</b> Evidence from predictive tools (except for splicing impact predictors) may be used in combination with evidence from protein impact assays (PS3)
	PP3	PS3	
	PVS1	PS3	
14	PM5	PS3	<b>Restriction:</b> PM5 and PS1 can only be applied in combination with PS3 if the reference variant can be classified as (likely) pathogenic without the use of functional data, and no splicing effect is predicted with prediction tools or suggested through results from functional assays.
	PS1	PS3	
15	PP3	PVS1_RNA	<b>Not permitted:</b> If PVS1_RNA has been applied, predictive codes (PP3, PM4, and PVS1) may not also be applied for splicing impact prediction, although results from splicing predictions may be used to validate application of PVS1_RNA (per Walker et al, 2023 <sup>10</sup> )
	PM4	PVS1_RNA	
	PVS1	PVS1_RNA	
16	PVS1_RNA	PS1	<b>Caution:</b> Per advice from the ClinGen SVI Splicing Subgroup Response to Feedback document, PS1 and PVS1_RNA may be used in combination provided that there is a relevant pathogenic variant with the same predicted impact as the variant under assessment (for further details, see: the table in the PS1 section of this document, Table 2 of Walker et al., 2023 <sup>10</sup> , and the ClinGen SVI Splicing Subgroup Response to Feedback document <sup>11</sup> )
17	PVS1_RNA	PS3	<b>Restriction:</b> PS3 and PVS1_RNA may be used in combination only if the two criteria together do not exceed 8 evidence points (very strong). For example, PS3_MOD + PVS1_RNA_STR (total of 6 points) is permitted, but PS3_MOD + PVS1_RNA_VSTR (total of 10 points) is not.
18	PP4	PM3	<b>Caution:</b> PP4 can not be used for subphenotypic elements which themselves have been used in the case-definition of specific phenotype for PM3
	PP4	PP1	<b>Caution:</b> PP4 can not be used for subphenotypic elements which themselves have been used in the case-definition of specific phenotype for segregation
19	PM3	PP1	<b>Caution:</b> if identification <i>in trans</i> is part of evaluation of co-segregation, these elements can not both be counted

## Combinations: towards benignity



1	BP7_RNA	BS3	<b>Restricted:</b> BS3 and BP7_RNA may be used in combination only if the two criteria together do not exceed 8 evidence points (very strong).
2	BS2	BS4	<b>Caution:</b> if identification in trans is part of evaluation of co-segregation, these elements can not both be counted
3	BS2	BP2	<b>Not permitted:</b> in recessive context BS2 is used for homozygosity; BP2 for heterozygosity
4	BS4	BP2	<b>Caution:</b> if identification in trans is part of evidence against co-segregation, these elements can not both be counted
5	BS3	BP4	<b>Restricted:</b> Evidence from predictive tools (except for splicing impact predictors) is permitted where a protein impact assay within PS3 is applied
6	BP3	BP4	<b>Not permitted:</b> BP3 already recognises sequence context
7	BS4	BP5	<b>Caution:</b> BP5 can not be used for alternative explanation where also used in same individual as evidence for non-segregation
8	BP2	BP5	<b>Not permitted</b> together
9	BP4	BP7	<b>Caution:</b> absence of predicted splicing effect must be confirmed using in silico tools

Revised version	Date	Section	Update	Amended by	Approved by
2.15	02/12/2021	PS4	Case counting approach available for BRCA1/BRCA2 genes	Garrett	CStAG
2.15	02/12/2022	PVS1	Clarification regarding stop gain variants within the first 100 bp of the gene and use of CNV guidance for large insertions/deletions	Garrett	CStAG
2.15	02/12/2022	Combinations	PS3 splicing assays and PM4 not to be used in combination, correction of typo in point 15	Garrett	CStAG
2.15	04/01/2022	PS1	Clarification that exact same amino acid change required for strong application	Garrett	Turnbull
2.16	06/01/2022	PP4	Amendment of examples for scoring so consistent with MMR gene specific guidance, addition of SDHx example	Turnbull	CStAG
2.17	28/07/2022	PS1	PS1 wording change in line with ACGS 2022. Clarification on mechanism of pathogenicity for reference missense variants	Allen	CStAG
2.17	22/09/2022	PVS1	Addition of guidance regarding +2T>C variants in PVS1 in line with ACGS	Allen/ Garrett	CStAG
2.17	22/09/2022	Guidance notes	Guidance on when to use CanVIG-UK consensus specification and when to use CNV guidance for insertions and deletions. General guidance on use of HGVS nomenclature.	Allen/ Garrett	CStAG
2.17	22/09/2022	PS4	Addition of guidance for when ancestry is unknown and minimum number of cases required for PS4 application specified.	Garrett	CStAG
2.17	22/09/2022	PS4/PM2	Recommended caution for use of PS4/PM2 for insertions/deletions >10bp. Specified use of DGV Gold and insertion/deletion sizes that are appropriate for PM2_sup.	Garrett/ Allen	CStAG
2.17	24/11/2022	PS1	Removal of canonical splice variants and altering strength of application for non-canonical splice variants. Addition of SpliceAI requirement.	Allen	CStAG
2.17	24/11/2022	PM5	Specified thresholds for REVEL score difference between reference and variant under examination in line with SVI recommendations.	Garrett/ Allen	CStAG
2.17	24/11/2022	PP5/BP6	Removed expert panel application.	Allen	CStAG
2.17	24/11/2022	BP7	Specified BP4 must be applied in tandem, and definition added for non-conserved regions.	Allen	CStAG
2.18	05/05/2023	PS4	Clarification regarding use of PS4 where PM2 cannot be applied, UK Biobank replaced gnomAD v2.1.1 as recommended population control data source. Rewording of explanatory notes re: case-counting.	Allen/ Garrett	CStAG
2.18	05/05/2023	PVS1	Amended link to Tayoun et al. decision tree	Allen	CStAG
2.18	26/05/2023	PM2	Updated guidance on population database use and frequency thresholds.	Garrett/ Allen	CStAG
2.18	03/07/2023	PM5	Clarification of application of PM5_supporting when REVEL score <0.773.	Garrett	CStAG
2.18	04/07/2023	Combinations	PVS1- PM5 combination amended to "caution" due to gene-specific recommendations for protein truncating variants.	Garrett/ Allen	CStAG
2.18	15/09/2023	BA1/BS1	Specification regarding use of the gnomAD filtering allele frequency	Callaway/ McDevitt	CStAG
2.18	28/09/2023	PVS1	Clarification of PVS1 use for stop codon variants	McDevitt	CStAG

2.19	01/05/2024	PS4	For CNVs: Removed evidence cap at supporting for case-control data, but require downgrade by single level of evidence strength	Allen	CStAG
2.19	01/05/2024	PS4	For CNVs: Removed requirement for PS4 case-counting to be downgraded from moderate to supporting, but require PM2 to be applied and require no CNV overlap in population data when applying PM2.	Allen	CStAG
2.19	01/05/2024	PS4	Moved CNV case-counting recommendations under the case-counting section of PS4	Allen	CStAG
2.19	22/02/2024	PM2	PM2 and PS4 may be used in combination for CNVs if different population-bases control datasets have been used.	Allen	CStAG
2.19	01/05/2024	PM2	PM2_moderate may be used for CNVs	Allen	CStAG
2.19	01/05/2024	PS4/PM2/ BA1/BS1	Updated population databases and terminology to refer to gnomAD v4.1 (or the UK Biobank partition of gnomAD v4.1 for case-control evidence under PS4)	Allen	CStAG
2.19	01/05/2024	PM2	Added note that UK Biobank allele counts for in/dels and SNVs can be found on CanVar-UK	Allen	CStAG
2.19	23/05/2024	PM2	Clarification of frequency with respect to both individuals and alleles.	CStAG	CStAG
2.19	01/05/2024	PM5	Added clarification that PM5_sup requires REVEL to be >0.7 as well as <0.773	Allen	CStAG
2.19	01/05/2024	Combinations	Added clarification that PM1 may not be used with PS3 or BS3	Allen	CStAG
2.19	01/05/2024	Combinations	Removed PP5 and BP6 as these evidence codes are no longer valid.	Allen	CStAG
2.19	13/05/24	Guidance notes	Requirement of ≥2 concordant evidence items for non-VUS overall classifications	Garrett	CStAG
3.00	25/07/2024	PM5	Terminology update ('equivalent score' to 'similar/higher score')	Allen	CStAG
3.00	25/07/2024	BS2/BP2	Addition of <i>BRCA1</i> to example genes list	Burghel	CStAG
3.00	25/07/2024	PS4/PM2	Added clarification on use of gnomAD v4.1 databases for different CNV sizes.	Callaway	CStAG
3.00	30/07/2024	Guidance Notes	Updated ACGS reference to the 2024 version of the Best Practice Guidelines	Allen	CStAG
3.00	13/12/2024	PS3/BS3/ PVS1_RNA/ BP7_RNA	Addition of new guidance for functional studies: PS3/BS3 now for protein impact, PVS1_RNA/BP7_RNA (new codes) now for splicing impact studies. In-line with Walker et al., 2023 ClinGen SVI guidelines.	CStAG	CStAG
3.00	13/12/2024	PS1	Guidance updated to match the Walker et al., 2023 guidelines for PS1. Includes addition of PS1 strength table, definition of variants with similar/higher predictive scores, specification that variant under examination must have the same mechanism of action as the reference variant.	CStAG	CStAG
3.00	13/12/2024	Combinations	Update to combinations tables to accommodate Walker et al. 2023 guidelines and functional/splicing impact assays (new codes: PVS1_RNA and BP7_RNA included)	Allen	CStAG

## References

1. Durkie M, Cassidy E-J, Berry I, et al. ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2024. 2024-02-20 2024;
2. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). *Genetics in Medicine*. 02/2020 2020;22(2):245-257. doi:10.1038/s41436-019-0686-8
3. Lee K, Krempely K, Roberts ME, et al. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline *CDH1* sequence variants. *Human Mutation*. 11/2018 2018;39(11):1553-1568. doi:10.1002/humu.23650
4. Fortuno C, Lee K, Olivier M, et al. Specifications of the ACMG/AMP variant interpretation guidelines for germline *TP53* variants. *Human Mutation*. 03/2021 2021;42(3):223-236. doi:10.1002/humu.24152
5. Mester JL, Ghosh R, Pesaran T, et al. Gene-specific criteria for *PTEN* variant curation: Recommendations from the ClinGen *PTEN* Expert Panel. *Human Mutation*. 11/2018 2018;39(11):1581-1592. doi:10.1002/humu.23636
6. Abou Tayoun AN, Pesaran T, DiStefano MT, et al. Recommendations for interpreting the loss of function *PVS1* ACMG/AMP variant criterion. *Human Mutation*. 11/2018 2018;39(11):1517-1524. doi:10.1002/humu.23626
7. Lindeboom RGH, Supek F, Lehner B. The rules and impact of nonsense-mediated mRNA decay in human cancers. *Nature Genetics*. 10/2016 2016;48(10):1112-1118. doi:10.1038/ng.3664
8. Chen J-M, Lin J-H, Masson E, et al. The Experimentally Obtained Functional Impact Assessments of 5' Splice Site GT>GC Variants Differ Markedly from Those Predicted. *Current Genomics*. 2020-03-25 2020;21(1):56-66. doi:10.2174/1389202921666200210141701
9. Talukdar S, Hawkes L, Hanson H, et al. Structural Aberrations with Secondary Implications (SASIs): consensus recommendations for reporting of cancer susceptibility genes identified during analysis of Copy Number Variants (CNVs). *Journal of Medical Genetics*. 11/2019 2019;56(11):718-726. doi:10.1136/jmedgenet-2018-105820
10. Walker LC, Hoya MDL, Wiggins GAR, et al. Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup. *The American Journal of Human Genetics*. 07/2023 2023;110(7):1046-1067. doi:10.1016/j.ajhg.2023.06.002
11. ClinGen SVI Splicing Subgroup dynamic document - Response to feedback. Accessed 06/12/2024, [https://clinicalgenome.org/site/assets/files/9588/clingen\\_svi\\_splicing\\_subgroup\\_dynamic\\_document\\_-\\_response\\_to\\_feedback.pdf](https://clinicalgenome.org/site/assets/files/9588/clingen_svi_splicing_subgroup_dynamic_document_-_response_to_feedback.pdf)
12. Pejaver V, Byrne AB, Feng B-J, et al. Evidence-based calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for clinical use of PP3/BP4 criteria. 2022-03-19 2022;doi:10.1101/2022.03.17.484479
13. Gunning AC, Fryer V, Fasham J, et al. Assessing performance of pathogenicity predictors using clinically relevant variant datasets. *Journal of Medical Genetics*. 08/2021 2021;58(8):547-555. doi:10.1136/jmedgenet-2020-107003
14. Wai HA, Lord J, Lyon M, et al. Blood RNA analysis can increase clinical diagnostic rate and resolve variants of uncertain significance. *Genetics in Medicine*. 06/2020 2020;22(6):1005-1014. doi:10.1038/s41436-020-0766-9
15. Houdayer C, Caux-Moncoutier V, Krieger S, et al. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on *BRCA1* and *BRCA2* variants. *Human Mutation*. 08/2012 2012;33(8):1228-1238. doi:10.1002/humu.22101

16. Brnich SE, Abou Tayoun AN, Couch FJ, et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. *Genome Medicine*. 2019-12-31 2019;12(1):3. doi:10.1186/s13073-019-0690-2
17. Jarvik GP, Browning BL. Consideration of Cosegregation in the Pathogenicity Classification of Genomic Variants. *The American Journal of Human Genetics*. 06/2016 2016;98(6):1077-1081. doi:10.1016/j.ajhg.2016.04.003
18. Garrett A, Loveday C, King L, et al. Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, SDHB and SDHD. *Genetics in Medicine*. 01/2022 2022;24(1):41-50. doi:10.1016/j.gim.2021.08.004
19. Ghosh R, Harrison SM, Rehm HL, Plon SE, Biesecker LG, Group oboCSVIW. Updated recommendation for the benign stand-alone ACMG/AMP criterion. *Human Mutation*. 11/2018 2018;39(11):1525-1530. doi:10.1002/humu.23642